Constipation and changes in the gut flora in Parkinson’s disease (2)
Research type
Research Study
Full title
Constipation and changes in the gut flora in Parkinson’s disease: A Pilot Study
IRAS ID
278797
Contact name
Isobel Sleeman
Contact email
Sponsor organisation
University of Aberdeen
Duration of Study in the UK
0 years, 5 months, 28 days
Research summary
Parkinson’s disease (PD) is a common, age-related neurological condition, affecting approximately 145,000 people in the United Kingdom. Diagnostic symptoms include stiffness, tremor, unsteadiness and slow movements. Interestingly, while PD is usually considered to be a neurological condition, pathological changes occur in the gut years before diagnosis, often causing constipation. As such, the gut has attracted attention as a possible therapeutic target.
Previous studies have shown different profiles of gut bacteria and the short chain fatty acids (SCFA) they produce in people with PD. There is evidence these changes might be significant to the disease course, as faecal transplants from people with PD worsened symptoms in a mouse model of PD. The mechanism for this is unclear, but changes in short chain fatty acids and gut wall inflammation, have both been suggested. Studies so far have compared gut bacteria in people with and without PD, however, as the healthy controls often don’t have constipation, it is unclear if the differences seen are due to PD itself or the associated constipation.
This pilot study aims to determine differences in the frequency of gut micro-organisms (bacteria, fungi and archaea) and gut function, other than those caused by constipation. 40 participants with a new diagnosis of PD will be recruited from Movement Disorder clinics within National Health Service (NHS) Grampian. 40 healthy (non-PD) controls will be recruited from the PD participants households. All 80 participants clinically assessed and asked to provide two stool samples. The samples will be analysed for the frequency of gut micro-organisms, changes in gut function (short chain fatty acid concentrations) and gut inflammation (calprotectin concentrations).
The aim of this pilot study is to determine the key differences in gut micro-organisms in PD compared to controls, which may have a role in disease progression. It is likely that the results of this study would need to be confirmed in a larger trial before we were able to plan an intervention trial, such as testing a prebiotic product, with the aim of normalising gut micro-organisms, and potentially modifying the disease course.
REC name
London - Hampstead Research Ethics Committee
REC reference
22/PR/1265
Date of REC Opinion
28 Oct 2022
REC opinion
Further Information Favourable Opinion